AU2011345341B2 - Novel 19-nor-steroids and their use for treating progesterone-dependent conditions - Google Patents

Novel 19-nor-steroids and their use for treating progesterone-dependent conditions Download PDF

Info

Publication number
AU2011345341B2
AU2011345341B2 AU2011345341A AU2011345341A AU2011345341B2 AU 2011345341 B2 AU2011345341 B2 AU 2011345341B2 AU 2011345341 A AU2011345341 A AU 2011345341A AU 2011345341 A AU2011345341 A AU 2011345341A AU 2011345341 B2 AU2011345341 B2 AU 2011345341B2
Authority
AU
Australia
Prior art keywords
compound
administered
salt
alkyl
progesterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011345341A
Other languages
English (en)
Other versions
AU2011345341A1 (en
Inventor
Joseph S. Podolski
Ronald D. Wiehle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals International Ltd
Original Assignee
Allergan Pharmaceuticals International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/062068 external-priority patent/WO2011119194A1/en
Application filed by Allergan Pharmaceuticals International Ltd filed Critical Allergan Pharmaceuticals International Ltd
Publication of AU2011345341A1 publication Critical patent/AU2011345341A1/en
Application granted granted Critical
Publication of AU2011345341B2 publication Critical patent/AU2011345341B2/en
Assigned to Allergan pharmaceuticals International Ltd. reassignment Allergan pharmaceuticals International Ltd. Request for Assignment Assignors: REPROS THERAPEUTICS INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2011345341A 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions Ceased AU2011345341B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2010/062068 WO2011119194A1 (en) 2010-03-22 2010-12-23 Compositions and methods for non-toxic delivery of antiprogestins
AUPCT/US2010/062068 2010-12-23
PCT/US2011/050859 WO2012087389A1 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Publications (2)

Publication Number Publication Date
AU2011345341A1 AU2011345341A1 (en) 2013-07-04
AU2011345341B2 true AU2011345341B2 (en) 2016-10-20

Family

ID=44681424

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011345341A Ceased AU2011345341B2 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Country Status (13)

Country Link
US (1) US20130274234A1 (enExample)
EP (1) EP2655394A1 (enExample)
JP (2) JP2014500316A (enExample)
KR (1) KR20130132955A (enExample)
CN (1) CN103403017A (enExample)
AU (1) AU2011345341B2 (enExample)
CA (1) CA2820877A1 (enExample)
MX (1) MX2013006732A (enExample)
NZ (1) NZ612295A (enExample)
SG (1) SG191207A1 (enExample)
UA (1) UA113283C2 (enExample)
WO (1) WO2012087389A1 (enExample)
ZA (1) ZA201304381B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) * 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US10064815B2 (en) * 2014-05-05 2018-09-04 Repros Therapeutics Inc. Formulations and methods for vaginal delivery of antiprogestins

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
JPH0830004B2 (ja) 1983-11-14 1996-03-27 コロンビア ラボラトリーズ インコーポレイテッド 生物接着性組成物およびそれにより治療する方法
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
ES2152671T3 (es) * 1996-05-01 2001-02-01 Us Gov Health & Human Serv Derivados de progesterona sustituidos en posicion 21 como nuevos agentes antiprogestacionales.
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6020328A (en) 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
ATE396197T1 (de) * 2000-03-17 2008-06-15 Us Gov Health & Human Serv 17-alpha-substituierte-11-beta-substituierte-4- aryl und 21-substituierte 19-norpregnadienedione mit antigestagener aktivität
MY150763A (en) * 2006-10-24 2014-02-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs

Also Published As

Publication number Publication date
MX2013006732A (es) 2013-07-17
SG191207A1 (en) 2013-07-31
CA2820877A1 (en) 2012-06-28
JP2014500316A (ja) 2014-01-09
JP2016180004A (ja) 2016-10-13
UA113283C2 (xx) 2017-01-10
CN103403017A (zh) 2013-11-20
ZA201304381B (en) 2014-03-26
KR20130132955A (ko) 2013-12-05
US20130274234A1 (en) 2013-10-17
WO2012087389A1 (en) 2012-06-28
AU2011345341A1 (en) 2013-07-04
EP2655394A1 (en) 2013-10-30
NZ612295A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
US20150203526A1 (en) Novel 19-nor-steroids and their use for treating progesterone- dependent conditions
JP2018062530A (ja) プロゲステロン依存性病態を処置する方法およびその組成物
US20130274234A1 (en) Novel 19-nor-steroids and their use for treating progesterone- dependent conditions
JP2010516686A (ja) ステロイド誘導体の安定性向上のための方法
HK1191339A (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
HK1240111A (en) Compositions and methods for non-toxic delivery of antiprogestins
HK1240111A1 (en) Compositions and methods for non-toxic delivery of antiprogestins
HK1240094A (en) Compositions and methods for non-toxic delivery of mifepristone
HK1240094A1 (en) Compositions and methods for non-toxic delivery of mifepristone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired
PC Assignment registered

Owner name: ALLERGAN PHARMACEUTICALS INTERNATIONAL LTD.

Free format text: FORMER OWNER(S): REPROS THERAPEUTICS INC.